Continuous treatment of plaque-type psoriasis with etanercept: an observational long-term experience

International Journal of Immunopathology and Pharmacology
Maria EspositoSergio Chimenti

Abstract

To assess the long-term efficacy and safety profile and the patient-reported outcomes (PRO) in patients with moderate-to-severe plaque-type psoriasis receiving continuous etanercept treatment. An open-label study was conducted to evaluate etanercept as long-term treatment for moderate-to-severe plaque psoriasis. Continuous therapy was administered at a dose of 50 mg subcutaneously twice weekly for 12 weeks followed by a continuous treatment with 50 mg subcutaneously once weekly or 25 mg twice weekly throughout a 96-week study. The primary measure of efficacy was the proportion of patients with PASI 75 at week 24, 48 and 96. Patient-reported outcomes (PRO) were also assessed during the study, at week 24, 48 and 96, including the Dermatology Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI). At baseline, mean PASI score, DLQI and PDI for patients eligible to initiate treatment with etanercept showed significant disease severity, quality-of-life impairment and psoriasis-related disability. At week 96, patients showed statistically significant and meaningful improvements. The continuous etanercept regimen provided a consistent improvement in both clinical disease parameters and PRO measures.

References

Jan 1, 1978·Dermatologica·T Fredriksson, U Pettersson
Jan 1, 1987·Clinical and Experimental Dermatology·A Y Finlay, S E Kelly
Feb 1, 1995·The British Journal of Dermatology·A Y Finlay, E C Coles
May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Feb 9, 2002·Dermatology : International Journal for Clinical and Investigative Dermatology·Damiano AbeniMary Margaret Chren
Nov 25, 2003·The New England Journal of Medicine·Craig L LeonardiUNKNOWN Etanercept Psoriasis Study Group
Dec 17, 2003·Archives of Dermatology·Alice B GottliebRalph Zitnik
Feb 12, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·Alice B Gottlieb
Apr 16, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·Victoria Lewis, Andrew Y Finlay
Apr 17, 2004·Experimental Dermatology·Arndt J G SchotteliusCarl K Edwards
Jun 8, 2004·Current Drug Targets. Inflammation and Allergy·Luigi Naldi
Nov 23, 2006·Journal of the American Academy of Dermatology·Angela MooreSeth R Stevens
Jun 20, 2007·Archives of Dermatology·Stephen TyringAngelika Jahreis
Jan 18, 2008·The New England Journal of Medicine·Amy S PallerUNKNOWN Etanercept Pediatric Psoriasis Study Group
Mar 25, 2009·International Journal of Immunopathology and Pharmacology·M EspositoS Chimenti

❮ Previous
Next ❯

Citations

Jun 13, 2013·International Journal of Immunopathology and Pharmacology·D Rigante, S Esposito
Oct 21, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·T LugerP A Löschmann
Feb 2, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·M EspositoG Girolomoni
Jun 24, 2016·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Susanna EspositoNicola Principi
Apr 14, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·J C PrinzG Girolomoni
Dec 14, 2012·Dermatology : International Journal for Clinical and Investigative Dermatology·Lluís PuigCarmen García-Calvo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.